Showing 1,510 results

Filters Content type: News, Editors' picks Topic: Pharmaceutical industry

News and information on drug companies, the cost of therapies, patent protections and generic medicines.

Pharmaceutical industry

Boehringer Ingelheim exits virology research as hep C drugs move down pipeline

Editor's pick
Pharma Times
20 September 2012
New & experimental HIV treatments

Avexa’s HIV integrase inhibitors show activity against drug-resistant HIV with potential for once-daily dosing

Editor's pick
Avexa press release
20 September 2012
New & experimental hepatitis C treatment

Medgenics' Bulging Pipeline Of Blockbuster Indications Takes On Big Pharma's Harmful Drugs

Editor's pick
Seeking Alpha
19 September 2012
Pharmaceutical industry

Gilead's HIV pill could be market leader in 3-5 years: JP Morgan

Editor's pick
CNBC
18 September 2012
Access to healthcare

Gilead Sciences, Task Force Agree to ADAP Price Discount for Stribild

Editor's pick
AIDSMeds.com
10 September 2012
Side effects

Salix Says FDA Decision Delayed on HIV-Associated Diarrhea Drug

Editor's pick
Bloomberg
6 September 2012
Pharmaceutical industry

High-End HIV Drug Stribild To Set Gilead Sciences Apart

Editor's pick
Seeking Alpha
6 September 2012
Drug-resistant TB

Janssen-Cilag International NV (Janssen) Submits European Marketing Authorisation Application for Investigational Multi-Drug Resistant Tuberculosis Treatment Bedaquiline

Editor's pick
Janssen-Cilag press release
3 September 2012
New & experimental hepatitis C treatment

Achillion Deal Looming as Hepatitis Drugs Fail: Real M&A

Editor's pick
Business Week
30 August 2012
Pharmaceutical industry

Quad approved in US: exorbitant cost likely to block use in Europe

Editor's pick
HIV i-Base
28 August 2012
New & experimental HIV treatments

F.D.A. Approves Once-a-Day Pill for H.I.V.

Editor's pick
New York Times
28 August 2012
Pharmaceutical industry

AIDS pill's price tag draws criticism

Editor's pick
San Francisco Chronicle
24 August 2012
New & experimental hepatitis C treatment

Bristol-Myers Squibb Discontinues Development of BMS-986094, an Investigational NS5B Nucleotide for the Treatment of Hepatitis C

Editor's pick
Bristol Myers Squibb press release
24 August 2012
Changing treatment

Are antiretroviral switch or simplification studies of benefit for patients?

News
15 August 2012
Access to healthcare

AIDS Sufferers Seen Hurt in Pacific Trade Pact Limits

Editor's pick
Business Week
9 August 2012
Pharmaceutical industry

Bristol-Myers Halts Hepatitis C Trial as Pipeline Stumbles - OregonLive.com

Editor's pick
Oreegonlive.com
8 August 2012
New & experimental hepatitis C treatment

Achillon hep C drug shows promise in mid-stage study

Editor's pick
Reuters
8 August 2012
Pharmaceutical industry

Bristol-Myers Squibb executive arrested on insider trading charges

Editor's pick
hepatitiscnewdrugs.blogspot.com
3 August 2012
Pharmaceutical industry

Gilead Sciences Announces New Collaboration with Indian Partners to Reduce Manufacturing Cost and Improve Availability of Emtricitabine-Based Antiretroviral Therapy in Developing Countries

Editor's pick
Bloomberg Business Week
2 August 2012
New & experimental hepatitis C treatment

Like Gilead, Achillion Should Trade Up On Bad News For Bristol-Myers, Idenix

Editor's pick
Reuters
2 August 2012
Adherence

Digital pills make their way to market

Editor's pick
Nature
2 August 2012
New & experimental hepatitis C treatment

Gilead Begins Single Pill Hepatitis C Study for 2014 Approval

Editor's pick
Businessweek
29 July 2012
Finance & funding

First generic HIV drugs could save US at least $920 million a year

News
27 July 2012
Access to healthcare

United States trade policy undermines access to anti-retroviral medicines

Editor's pick
Oxfam
25 July 2012